AXON - Axon Enterprise, Inc.
Arizona State Retirement System grew its holdings in Axon Enterprise, Inc (NASDAQ: AXON) by 7.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 21,898 shares of the biotechnology company's stock after acquiring an additional 1,528 shares during the quarter. Arizona State Retirement
In the latest trading session, Axon Enterprise (AXON) closed at $490, marking a -3.05% move from the previous day.
Axon Enterprise, Inc. (NASDAQ:AXON) shares are trading sideways Wednesday. They have found support at an important price level.
Concurrent Investment Advisors LLC raised its stake in Axon Enterprise, Inc (NASDAQ: AXON) by 200.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,889 shares of the biotechnology company's stock after buying an additional 3,260 shares during the quarter.
Axon Enterprise, Inc. (AXON) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
California State Teachers Retirement System increased its holdings in shares of Axon Enterprise, Inc (NASDAQ: AXON) by 55,955.7% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 64,781,849 shares of the biotechnology company's stock after purchasing an additional 64,666,282 shares during the
Axon (AXON) reported earnings 30 days ago. What's next for the stock?
AXON's Connected Devices revenues surge 34.6%, fueled by TASER 10, counter-drone equipment and strong international bookings.
During the quarter, we initiated a position in Advanced Drainage Systems, the leading U.S. manufacturer of stormwater and onsite wastewater management products. We view Axon Enterprise as a market leading "atoms plus electrons" software provider with huge competitive moats. We sold the HeartFlow position in the quarter as we grew incrementally more concerned with the presence of competitors on the market.
The transaction involved the disposal of 16,775 shares on Aug. 31, 2026, for a total value of ~$9.6 million. The traded shares represented 5% of the direct equity stake held before the filing.
On Sept. 1, 2026, rising crude and Treasury yields pressured equities across nearly every sector, with tech stocks bearing the brunt of the selloff.
Shares of Axon Enterprise Inc. (NASDAQ:AXON) are sliding Tuesday afternoon, dropping nearly 8% to hover near $522 after falling over 5% during Monday's session.
Axon's Dedrone C2 upgrades, strategic partnerships and rising CUAS demand are fueling momentum after revenues topped $100 million in Q2 2026.
Bamco Inc. NY acquired a new stake in shares of Axon Enterprise, Inc (NASDAQ: AXON) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 153,615 shares of the biotechnology company's stock, valued at approximately $86,118,000. Bamco Inc. NY owned about 0.19% of
Axon Enterprise currently demonstrates a more consistent pattern of sequential revenue expansion across recent reporting periods, although Booking continuously generates a much larger total volume of absolute sales. Over the last eight quarters, Axon Enterprise recorded steady quarter-over-quarter revenue growth, whereas Booking exhibited a distinct cyclical pattern characterized by recurring peaks and subsequent sequential declines.
The disposition involved 9,605 shares, with a total transaction value of ~$6.0 million at a weighted-average price of $626.70 on Aug. 21, 2026. This transaction represents 5% of the reporting owner's total equity holdings in the company.
Bank of Nova Scotia bought a new position in shares of Axon Enterprise, Inc (NASDAQ: AXON) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,406 shares of the biotechnology company's stock, valued at approximately $3,587,000. A number of
TDY's 22.4% YTD gain, cheaper valuation and rising EPS estimates give it an edge over AXON despite strong growth.
Bank of New York Mellon Corp boosted its holdings in shares of Axon Enterprise, Inc (NASDAQ: AXON) by 3.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 730,899 shares of the biotechnology company's stock after purchasing an additional 22,068 shares during